Loading
Longeveron Inc. is a biotechnology company currently in the clinical development stage, dedicated to pioneering cell-based therapies. These treatments are designed to address both age-related conditions and various critical, life-threatening illnesses. The company's primary investigational product is LOMECEL-B, a sophisticated cellular therapy. This product is created from medicinal signaling cells that are cultivated and expanded after being harvested from the bone marrow of healthy young adult donors. Longeveron is actively conducting Phase 1 and Phase 2 clinical trials to evaluate LOMECEL-B's potential across a diverse range of indications. These include age-related frailty, Alzheimer's disease, metabolic syndrome, acute respiratory distress syndrome (ARDS), and hypoplastic left heart syndrome (HLHS). Established in 2014, Longeveron Inc. operates from its headquarters in Miami, Florida.
Previous close
$6.81
+$0.23 · +3.50%
Pre-market
$6.88
+$0.07 · +1.03%
Sep 8, 4:15 AM ET
Regular session · ET · Market data may be delayed.
Longeveron Inc. is a biotechnology company currently in the clinical development stage, dedicated to pioneering cell-based therapies. These treatments are designed to address both age-related conditions and various critical, life-threatening illnesses. The company's primary investigational product is LOMECEL-B, a sophisticated cellular therapy. This product is created from medicinal signaling cells that are cultivated and expanded after being harvested from the bone marrow of healthy young adult donors. Longeveron is actively conducting Phase 1 and Phase 2 clinical trials to evaluate LOMECEL-B's potential across a diverse range of indications. These include age-related frailty, Alzheimer's disease, metabolic syndrome, acute respiratory distress syndrome (ARDS), and hypoplastic left heart syndrome (HLHS). Established in 2014, Longeveron Inc. operates from its headquarters in Miami, Florida.
Day range
Current $6.81
52-week range
Current $6.81
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
32
Expensive
Sentiment
50
Mixed
Risk
66
High Risk
Momentum
28
Weakening
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Longeveron Inc. is a biotechnology company currently in the clinical development stage, dedicated to pioneering cell-based therapies. These treatments are designed to address both age-related conditions and various critical, life-threatening illnesses. The company's primary investigational product is LOMECEL-B, a sophisticated cellular therapy. This product is created from medicinal signaling cells that are cultivated and expanded after being harvested from the bone marrow of healthy young adult donors. Longeveron is actively conducting Phase 1 and Phase 2 clinical trials to evaluate LOMECEL-B's potential across a diverse range of indications. These include age-related frailty, Alzheimer's disease, metabolic syndrome, acute respiratory distress syndrome (ARDS), and hypoplastic left heart syndrome (HLHS). Established in 2014, Longeveron Inc. operates from its headquarters in Miami, Florida.
Day range
Current $6.81
52-week range
Current $6.81
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 1.2M USD | 2.39M USD | 709K USD | 1.22M USD | 1.31M USD |
| Cost of goods sold | 396K USD | 508K USD | 488K USD | 725K USD | 716K USD |
| Gross profit | 803K USD | 1.88M USD | 221K USD | 497K USD | 590K USD |
| Research and development | 12.04M USD | 8.14M USD | 9.07M USD | 9.37M USD | 7.09M USD |
| Selling, general, and administrative | 12.05M USD | 10.27M USD | 12.18M USD | 9.17M USD | 10.95M USD |
| Operating expenses | 24.09M USD | 18.41M USD | 21.25M USD | 18.54M USD | 18.05M USD |
| Interest expense | — | — | — | — | 4K USD |
| Depreciation and amortization | 1.23M USD | 958K USD | 946K USD | 893K USD | 914K USD |
| Operating income | −23.29M USD | −16.52M USD | −21.03M USD | −18.04M USD | −17.46M USD |
| Net income | −22.7M USD | −15.97M USD | −21.41M USD | −18.84M USD | −17.05M USD |
Company facts updated Sep 8, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$10.00
46.84% upsideLimited analyst sample: 4 ratings. Interpret the distribution with caution.
| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | Aug 27, 2026 | 1:10 | — | — |
Stock split | Mar 27, 2024 | 1:10 | — | — |
Effective Aug 27, 2026
1:10
Effective Mar 27, 2024
1:10
Funds reporting this stock among their holdings, ordered by reported position size.
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
